Current development in clinical trials: Issues old and new

Statistics in Medicine

Volumn 31, Issue 25, 2012, Pages 2944-2954

  Demets, David L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Adaptive design; Noninferiority design; Randomized trials; Surrogate markers

Indexed keywords

ADAPTIVE TRIAL; ARTICLE; CLINICAL EVALUATION; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; GENETICS; GENOMICS; GOLD STANDARD; HUMAN; INFORMATION PROCESSING; INFORMATIVE CENSORING; MEDICAL PRACTICE; NONINFERIORITY TRIAL; PATIENT CARE; RISK ASSESSMENT; STATISTICAL CONCEPTS; STUDY DESIGN; TYPES OF STUDY;

BIOLOGICAL MARKERS; COMPARATIVE EFFECTIVENESS RESEARCH; CONFIDENCE INTERVALS; FOLLOW-UP STUDIES; GENETICS, MEDICAL; HUMANS; MODELS, STATISTICAL; ODDS RATIO; PATIENT COMPLIANCE; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TIME FACTORS;

EID: 84867468040     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5405     Document Type: Article

References (39)

1. th edn. Springer-Verlag: New York, NY, 2010.
2. Halperin M, DeMets DL, Ware JH. Early methodological developments for clinical trials at the National Heart, Lung, and Blood Institute. Statistics in Medicine 1990; 9:881-892.
3. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Adenomatous polyp prevention on vioxx (APPROVe) trial investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma prevention trial. New England Journal of Medicine 2005; 352:1092-1102.
4. Lagakos SW. Time-to-event analysis for long term prevention trials - the APPROVe trial. New England Journal of Medicine 2006; 355:113-117.
5. Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson E, DeMets DL. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008; 372:1756-1764.
6. Temple R, Ellenberg SS. Placebo-controlled trials and active-control in the evaluation of new treatments. Part 1: ethical and scientific issues. Annals of Internal Medicine 2000; 133:455-463.
7. Hung HM, Wang SJ, O'Neill R. A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials. Biometrical Journal 2005; 47:28-36.
8. Fleming TR. Current issues in non-inferiority trials. Statistics in Medicine 2008; 27:317-332.
9. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL, For the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity in severe chronic heart failure. New England Journal of Medicine 1996; 335(15):1107-1114.
10. Thackray S, Witte K, Clark A, Cleland J. Clinical trials update, OPTIME-CHF, PRAISE-2, All-HAT. European Journal of Heart Failure 2000; 2:209-212.
11. Cook T, DeMets DL (eds). Introduction to Statistical Methods for Clinical Trials. Chapman & Hall/CRC; Taylor & Francis Group, LLC: Boca Raton, FL, 2008. p. 87.
12. The International Steering Committee on Behalf of the MERIT-HF Study Group. Rationale, design, and organization of the metoprolol CR/XL randomized intervention trial in heart failure (MERIT-HF). American Journal of Cardiology 1997; 30(9B):54J-58J.
13. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Staiger C, Curtin EL, Roecker EB, Schultz MK, DeMets DL, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of Carvedilol on survival in severe chronic heart failure. New England Journal of Medicine 2001; 334(22):1651-1658.
14. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial. Lancet 1999; 353:9-13.
15. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, Hennekens CH. Intravenous and intracoronary fibronolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33randomized controlled trials. European Heart Journal 1985; 6:556-585.
16. Yusuf S. Obtaining medically meaningful answers from an overview of randomized clinical trials. Statistics in Medicine 1987; 6:281-286.
17. Hennekens CH, Buring JE, Hebert PR. Implications of overviews of randomized trials. Statistics in Medicine 1987; 6:397-402.
18. Hennekens CH, DeMets DL, BaireyMerz CN, Borzak SL, Borer JS. Doing more good than harm: need for a cease fire. American Journal of Medicine 2009; 122(4):315-316.
19. Community Cancer Oncology Program:http://prevention.cancer.gov/programs-resources/programs/ccop.
20. Jacobson MA, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Neaton JD, Abrams D, Rimland D, Perez G, Grant IH, Saravolatz LD, Brown LS, Deyton L. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced HIV disease: Results of a randomized trial. Journal of Infectious Diseases 1994; 169:384-394.
21. Zerhouni EA. Translational Research: Moving Discovery to Practice. Clinical Pharmacology & Therapeutics 2007; 81:126-128.
22. Taubes G. Epidemiology faces its limits. Science 1995; 269:164-169.
23. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. IV. A preliminary report on phenformin results. Journal of the American Medical Association 1971; 217:777-784.
24. Coronary Drug Project Research Group. The Coronary Drug Project: initial findings leading to modifications of its research protocol. Journal of the American Medical Association 1970; 214:1303-1313.
25. Baigent C, Landray M. Study of heart and renal protection (SHARP). Kidney International Supplement 2003(Suppl84):S207-S210.
26. McFadden E, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Surruys PN. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364:1519-1521.
27. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skaerpe T, Wachtell K, Willenheimer R. SEAS Investigators. Intensive lipid lowering with simvistatin and ezetimibe in aortic stenosis. New England Journal of Medicine 2008; 359(13):1343-1356.
28. Peto R, Emberson J, Landray M, Baigent C, Collins R, Califf R. Analysis of cancer data from three ezetimibe trials. NewEngland Journal of Medicine 2008; 359:1-10.
29. Canner PL. Monitoring treatment differences in long-term clinical trials. Biometrics 1977; 33:603-615.
30. Cook T, DeMets DL. Review of draft FDA adaptive design guidance. Journal of Biopharmaceutical Statistics 2010; 20:1132-1142.
31. Chen JYH, DeMets DL, Lan KKG. Increasing the sample size when the unblinded interim result is promising. Statistics in Medicine 2004; 23(7):1023-1038.
32. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Peterson R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Genomic signatures to guide the use of chemotherapeutics. Nature in Medicine 2006; 12:1294-1300.
33. Coombes KR, Wang J, Baggerly KA. Microarrays: retracing steps. Nature in Medicine 2007; 13:1276-1277.
34. Baggerly KA, Coombes KR. Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology. Annals of Applied Statistics 2009; 3:1309-1334.
35. Reich ES. Cancer trial errors revealed. Nature 2011; 469:139-140.
36. Subramanian J, Simon R. Gene expression based prognostic signatures in lung cancer, ready for clinical use? Journal of the National Cancer Institute 2010; 102:464-474.
37. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Interventional Trial: Risk factor changes and mortality results. Journal of the American Medical Association 1982; 248:1465-1477.
38. Peto R, Emberson J, Landry M, Baigent C, Collins R, Clare R, Califf R. Analysis of cancer data from three ezetimibe trials. New England Journal of Medicine 2008; 359. DOI: 10.1056/NEYMa0806603.
39. Green S, Fleming T, O'Fallon J. Policies for monitoring and interim reporting of results. Journal of Clinical Oncology 1987; 5:1477-1484.